Clinical trial
Study of LJP 394 in Lupus Patients With History of Renal Disease
NCT00089804 · La Jolla Pharmaceutical Company, Industry · Terminated
Key facts
| NCT number | NCT00089804 |
|---|---|
| Title | Study of LJP 394 in Lupus Patients With History of Renal Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease |
| Acronym | ASPEN |
| Lead sponsor | La Jolla Pharmaceutical Company, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic, Lupus Nephritis |
| Intervention type | Drug |
| Interventions | abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline |
| Enrollment | 943 |
| Start date | Oct 1, 2004 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Aug 17, 2004 |
| Last update posted | Apr 1, 2009 |
| Countries | Argentina, Australia, Belarus, Brazil, Bulgaria, Czechia, Georgia, Germany, Hong Kong, Hungary, India, Indonesia and 18 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: